Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | THRB | P10828 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.41 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.41 |
| ▸ | LPAR2 | Q9HBW0 | 1/20 | 0.41 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | FPR2 | P25090 | 1/20 | 0.38 |
| ▸ | PROKR1 | Q8TCW9 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5332752 | 0.85 | TP53 (0.48) | L3MBTL1NAMPTCYP1A2GAACYP2C9 | |
| SCHEMBL5322483 | 0.83 | NAMPT (0.43) | L3MBTL1NAMPTCYP1A2GAACYP2C9 | |
| SCHEMBL5321672 | 0.83 | MAPK1 (0.47) | NAMPTNPC1CYP1A2GAACYP2C9 | |
| SCHEMBL16707807 | 0.83 | L3MBTL1 (0.41) | L3MBTL1NAMPTNPC1 | |
| SCHEMBL5322490 | 0.80 | GPR142 (0.46) | NAMPT | |
| SCHEMBL5359415 | 0.80 | HPGD (0.56) | NAMPTNPC1 | |
| SCHEMBL5325263 | 0.79 | CYP2C9 (0.49) | NAMPTCYP1A2GAACYP2C9CYP2C19 | |
| SCHEMBL5330616 | 0.79 | ALDH1A1 (0.44) | L3MBTL1NAMPTADRB2 | |
| SCHEMBL5328948 | 0.78 | ALDH1A1 (0.63) | NAMPTADRB2CYP1A2GAACYP2C9 | |
| SCHEMBL5323146 | 0.75 | ALDH1A1 (0.49) | NAMPTADRB2CYP1A2GAACYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2007135427-A1 | 1,4-DISUBSTITUTED PIPERAZINE AND 1,4-DISUBSTITUTED AZEPANE AS 11 -BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | claimed |
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | XIANG JASON SHAOYUN | 2010-02-04 | — | — | US | disclosed |
| US-7632838-B2 | 11-beta HSD1 inhibitors | WYETH (US) | 2009-12-15 | — | — | US | disclosed |
| EP-1981848-A2 | 11-BETA HSD1 INHIBITORS | Wyeth (US) | 2008-10-22 | — | — | EP | disclosed |
| WO-2007135427-A1 | 1,4-DISUBSTITUTED PIPERAZINE AND 1,4-DISUBSTITUTED AZEPANE AS 11 -BETA-HYDROXYSTEROID DEHYDROGENASE 1 INHIBITORS | ASTRAZENECA AB (SE) | 2007-11-29 | — | — | WO | disclosed |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | WYETH (US) | 2007-09-20 | — | — | US | disclosed |
| WO-2007092435-A2 | 11-BETA HSD1 INHIBITORS | WYETH (US) | 2007-08-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100029648-A1 | 11-Beta HSD1 Inhibitors | HSD11B1, HSD3B1, HSD11B2 | L3MBTL1 1721/4885THRB 930/4885NAMPT 812/4885 |
| US-20070219198-A1 | 11-Beta HSD 1 inhibitors | HSD11B1, HSD11B2, HSD3B1 | L3MBTL1 2300/4885THRB 743/4885NAMPT 897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.